The Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market is expected to register a CAGR of 4.4% to reach USD 4,312.2 million till 2023. Methicillin-resistant staphylococcus aureus (MRSA) is an infection caused by antibiotic-resistant strains of the pathogen. This infection is generally associated with invasive procedures such as surgeries, intravenous tubing, and sometimes through the skin to skin contact. MRSA drugs are used to kill or restrain methicillin-resistant staphylococcus aureus infection.

The increase in the prevalence of MRSA infections and number of hospitals, growing awareness about a bacterial infection, and increase in immuno-compromised population are expected to enhance the market growth. However, the high cost of novel MRSA drugs and hospital readmissions reduction program is projected to curb the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/2102 

Global MRSA Drugs Market Players

Some of the key players profiled in the report are Merck KGaA, Olon, Allergan, Baxter, Theravance Biopharma, Pfizer, Mylan N.V, Novartis, and others.

Regional Analysis

The Americas accounts for a significant market share owing to high expenditure on the health care. The fastest uptake of new drugs in the US drives the MRSA drugs market. Furthermore, concentration of the major healthcare companies in the developed countries of this region coupled with large insurance penetration is adding fuel to the market growth. Moreover, the US expend high amount on its healthcare, which accounts for 16% of total GDP that also increases the sale in MRSA drugs market.

Europe is the second largest market in the world due to high income and strong healthcare penetration. The European market growth is led by countries such as Germany and France. Italy is expected to be the fastest growing region over the assessment period. The strong pharmaceutical industry in Germany is a primary driver behind the dominance of this country in Europe. Southern Europe has a considerable high prevalence of MRSA as compared to Scandinavian region countries such as Iceland, Norway etc. which is driving the market faster in these nations.

Asia Pacific region is expected to grow rapidly; China and India are likely to lead this market due to the fast growing healthcare sector and large unmet needs over the forecast period. However Asian countries such as Indonesia, Vietnam, Japan, South Korea, Philippines, and Sri Lanka have higher prevalence and are expected to contribute highly to the market growth. The growing penetration of healthcare insurance in the Asia Pacific region is expected to drive the future MRSA drugs market in the region.

Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a moderate growth owing to poor economic and political conditions, and poor healthcare development.

Segmentation

The global MRSA drugs market has been segmented on the basis of drug class, MRSA types, disease indications, and end user.

Based on the drug class, the market has been segmented as sulfa drugs, tetracyclines, oxazolidinones, glycopeptide antibiotics, and other.

Based on the MRSA types, the market has been segmented as hospital-acquired (HA-MRSA) and community-acquired (CA-MRSA).

Based on the disease indications, the market has been segmented as skin infections, bone and joint infections, bacteremia, animal infections, and others.

Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/mrsa-drugs-market-2102